French 
English 
Chinese 
Russian MSC Therapy for Chronic Kidney Disease: What the 2025 Evidence Shows
A 2025 meta-analysis of 52 studies, real-world Taiwan data, and Mayo Clinic intraarterial delivery results — what nephrologists need to know about MSCs and CKD.
14Oct
23Sep
MSC Therapy for Pulmonary Fibrosis: 2026 Preclinical and Clinical Evidence Review
A medical review of MSC-based and MSC-derived EV therapies for idiopathic pulmonary fibrosis, covering meta-analysis data, immune-cloaked cell engineering, nebulized exosome delivery, gut-lung axis mechanisms, and active clinical trials.
07Sep
MSC Therapy for Ischemic Stroke: What a 2026 Umbrella Review and Network Meta-Analysis of 1,006 Patients Reveal
The 2026 evidence base for mesenchymal stem cell therapy in ischemic stroke includes a 26-study umbrella review and an 18-RCT network meta-analysis of 1,006 patients. MSCs were the only cell type to significantly reduce mortality. This medical review synthesizes the latest clinical data, mechanisms, active trials, and translational barriers.
04Sep
Pourquoi vos cellules souches ralentissent après 40 ans (et ce que la science fait pour y remédier)
Research shows MSC activity drops 40% by age 50. Learn what changes inside aging cells and three emerging therapies showing real results in 2026 clinical trials.
28Août
Essais cliniques sur les cellules souches mésenchymateuses : ce que l’ISCT de Dublin a révélé sur la réparation du ménisque, le transfert mitochondrial et l’approvisionnement en cellules
A medical review of MSC clinical trials 2026: key evidence from ISCT Dublin, a Japanese phase III synovial-MSC meniscal repair trial, bone marrow vs cord tissue OA data, and mitochondrial EV mechanisms.
27Août
Thérapie par cellules souches pour les lésions de la moelle épinière : que nous apprennent les recherches de 2026 sur la thérapie par cellules souches mésenchymateuses après une lésion de la moelle épinière ?
Japan approved the world’s first MSC therapy for spinal cord injury in 2018. Here’s what six years of real-world data and 2026 mechanism research tell us about where MSC therapy for SCI actually stands.
24Août
Que se passe-t-il pendant la semaine de convalescence après un traitement par cellules souches à Bangkok ?
Planning a trip to Bangkok for stem cell therapy involves more than just scheduling your procedure date. International patients need to know: What does the post-treatment recovery week actually look like? Whether receiving intravenous (IV) infusions or targeted joint injections, the vast majority of patients experience minimal downtime. Here is a...
22Août
Stem Cell Therapy for Erectile Dysfunction: A Patient’s Guide to the 2026 Evidence
Diabetic ED, post-prostatectomy ED, PDE5 non-responders — here’s what 2026 trials and clinical experience show for stem cell therapy: who is a candidate, what the procedure looks like, what it costs, and what to expect.
20Août
MSC Therapy for Multiple Sclerosis: What 17 Trials and Tell Us
MSCs are the most promising cell therapy in progressive MS, and 2026 added the mechanism papers and one well-controlled trial that finally make the case. Here’s what 17 trials, SMART-MS, and the new miRNA work mean for real patients.
20Août
MSC-Derived Exosomes for Myocardial Infarction: Delivery Systems, Mechanisms, and the Bench-to-Bedside Pipeline
Eight 2026 studies detail how MSC exosomes inhibit ferroptosis, deliver sustained paracrine signaling via hydrogels, and improve LVEF in rat MI models. Here is what translational researchers need to know before the first Phase 2 exosome trial reads out.